Skip to main content
SpringerLink
Log in

Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective: To investigate the significance of treatment with antithyroid drugs longer than 12 months on lasting remission in Graves’ hyperthyroid patients, and to study clinical and laboratory parameters of prognostic value. Patients: Fifty-two untreated Graves’ hyperthyroid patients were assigned at random to two therapeutic groups. They were treated with Carbimazole during 12 and 24 months in Group I (n= 28) and Group II (n= 24), respectively. Measurements: Serum levels of FT4, T3, sTSH and TSH receptor antibody (TRAb) were measured before starting treatment and at regular intervals during treatment and follow-up after drug withdrawal. We compared the relapse rate in both groups of patients, at short (2-yr) and long-term (5-yr) periods after drug withdrawal. Also, we compared clinical and biochemical parameters between patients who stayed in remission and who had relapse. Results: At the end of the short-term period, relapse had occurred in 13 (46.4%) Group I patients and in 13 (54.1%) Group II patients, p=0.36. At the end of the long-term period, relapse had occurred in 24 (85.7%) Group I and 20 (83.3%) Group II patients, p=0.78. No difference could be observed between patients who had stayed in remission and who had suffered relapse, within the 5-yr follow-up period regarding to goiter size, frequency of ophthalmopathy, TSH and TRAb levels. Conclusions: The high relapse rate observed could be due to high iodine intake in our country. In this study and in a review of the available data, we have been unable to find any rational basis for courses of antithyroid drugs longer than twelve months for the treatment of Graves’ hyperthyroidism. Nor is a reliable prognosis for an individual patient possible by TRAb determination at any given time during therapy, owing to the low sensitivity and specificity of this variable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Laurberg P., Hansen P.E., Iversen E., Jensen S.E., Weete J. Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol. (Copenh.) 111: 39, 1986.

    CAS  Google Scholar 

  2. Takamatsu J., Kuma K., Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves’ disease. J. Clin. Endocrinol. Metab. 62: 980, 1986.

    Article  CAS  PubMed  Google Scholar 

  3. Wilson R., McKillop J.H., Henderson N., Pearson D.W., Thomson J.A. The ability of the serum thyrotrophin receptor antibody (TRab) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves’ disease. Clin. Endocrinol. (Oxf.) 25: 151, 1986.

    Article  CAS  Google Scholar 

  4. Winsa A., Dahlberg P.A., Jansson R., Agren H., Karlsson F.A. Factors influencing the outcome of thyrostatic drug therapy in Graves’ disease. Acta Endocrinol. (Copenh.) 122: 622, 1990.

    Google Scholar 

  5. Hedley A.J., Young R.E., Jones S.J., Alexander W.D., Bewsher P.D., Scottish automated follow-up register group. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long-term follow-up of 434 patients. Clin. Endocrinol. (Oxf.) 31: 209, 1989.

    Article  CAS  Google Scholar 

  6. Schleusener H., Schwander J., Fisher C., Hollo R., Holl G., Badenhoop K., Hensen J., Finke R., Bogner U., Mayr W.R., Schernthaner G., Schatz H., Pickardt C.R., Kotulla P. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease. Acta Endocrinol. (Copenh.) 120: 689, 1989.

    CAS  Google Scholar 

  7. Tamai H., Nakagawa T., Fikino O., Shinzato S. Thionamide therapy in Graves’ disease: relation of relapse to duration of therapy. Ann. Intern. Med. 92: 488, 1980.

    Article  CAS  PubMed  Google Scholar 

  8. Lippe B.M., Landaw E.M., Kaplan S.A. Hyperthyroidism in children treated with long medical therapy: Twenty-five percent remission every two years. J. Clin. Endocrinol. Metab. 64: 1241, 1987.

    Article  CAS  PubMed  Google Scholar 

  9. Allannic H., Fauchet R., Orgiazzi J., Madec A.M., Genetet B., Lorcy Y., Le Guerrier A.M., Delambre C., Derennes V. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration. J. Clin. Endocrinol. Metab. 70: 675, 1990.

    Article  CAS  PubMed  Google Scholar 

  10. Schleusener H., Schernthaner G., Mayr W.R., Kotula P., Bogner U., Finke E., Meinhold H., Koppenhagen K., Wenzel K.W. HLA-DR3-DR4 and HLA-DR5 associated thyrotoxicosis: two different types of toxic diffuse goitre. J. Clin. Endocrinol. Metab. 56: 781, 1983.

    Article  CAS  PubMed  Google Scholar 

  11. Romaldini J.H., Bromberg N., Werner R.S., Tanaka L.M., Rodrigues H.F., Werner M., Farah C.S., Reis L.C.F. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 57: 563, 1983.

    Article  CAS  PubMed  Google Scholar 

  12. Pinchera A., Liberti P., Martino E., Fenzi G.F., Grasso L., Rovis L., Baschieri L., Doria G. Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. J. Clin. Endocrinol. Metab. 29: 231, 1969.

    Article  CAS  PubMed  Google Scholar 

  13. McGregor A.M., Petersen M.M., McLachlan S.M., Rooke P., Rees Smith B., Hall R. Carbimazole and the autoimmune response in Graves’ disease. N. Engl. J. Med. 303: 302, 1980.

    Article  CAS  PubMed  Google Scholar 

  14. Weetman A.P., McGregor A.M., Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves’ disease. Clin. Endocrinol. (Oxf.) 21: 163, 1984.

    Article  CAS  Google Scholar 

  15. Davies T.F., Yeo P.P.B., Evered D.C., Clark F., Rees Smith B., Hall R. Value of thyroid-stimulating antibody determination in predicting short-term thyrotoxicosis relapse in Graves’ disease. Lancet 1: 1181, 1977.

    Article  CAS  PubMed  Google Scholar 

  16. Teng C.S., Yeung R.T.T. Changes in thyroid stimulating antibody activity in Graves’ disease treated with antithyroid drugs and its relationship to relapse: a prospective study. J. Clin. Endocrinol. Metab. 50: 144, 1980.

    Article  CAS  PubMed  Google Scholar 

  17. Weetman A.P., Ratanachaiyavong S., Middleton G.W., Love W., John R., Owen G.M., Darke C., Lazarus J.H., Hall R., McGregor A.M. Prediction of outcome in Graves’ disease after Carbimazole treatment. Quart. J. Med. 59: 409, 1986.

    CAS  PubMed  Google Scholar 

  18. Mazzaferri E.L. In: Skillman T.G. (Ed.), Endocrinology case studies, ed. 2. Hans Huber Publishers, Bern 1975, p.13.

  19. Crooks J., Murray I.P.C., Wayne E.J. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Quart. J. Med. 28: 211, 1959.

    CAS  PubMed  Google Scholar 

  20. García-Mayor R.V.G., Gómez Sobreira M., Batista J., Moreiras M., Lázaro Enguis J., Alvarez Gándara D. Disfunción tiroidea clínica en pacientes tratados crónicamente con amiodarona. Rev. Esp. Cardiol. 43: 227, 1990.

    Google Scholar 

  21. García-Mayor R.V.G., Cobas P. Resultados del tratamiento de la enfermedad de Basedow-Graves con antitiroideos. Estudio prospectivo. Endocrinologia 29: 56, 1982.

    Google Scholar 

  22. Rios Santomé M., García-Mayor R.V.G., Fernández M., Lago Y., Blanco V., Vázquez E. El bocio endémico en el sur de Galicia. Estudio epidemiológico. Ann. Med. Inter. (Madrid) 4: 379, 1987.

    Google Scholar 

  23. Wartofsky L. Low remission after therapy for Graves’ disease. Possible relation of dietary iodine with antithyroid therapy results. JAMA 226: 1083, 1973.

    Article  CAS  PubMed  Google Scholar 

  24. Yamamoto M., Igarashi T., Kimura S., Tsukamoto S., Togawa K., Ogata E. Thyroid suppression test and outcome of hyperthyroidism treated with antithyroid drugs and triiodothyronine. J. Clin. Endocrinol. Metab. 48: 72, 1979.

    Article  CAS  PubMed  Google Scholar 

  25. Hershman J.M., Givens J.R., Cassidy C.E., Astwood E.B. Long-term outcome of hyperthyroidism treated with antithyroid drugs. J. Clin. Endocrinol. Metab. 26: 803, 1966.

    Article  CAS  PubMed  Google Scholar 

  26. Glinoer D., Hesch D., Lagasse R., Laurberg P. The management of hyperthyroidism due to Graves’ disease in Europe in 1986. Results of an international survey. Acta Endocrinol. (Copenh.) 115 (Suppl. 185): 1, 1987.

    Google Scholar 

  27. Slingerland D.W., Burrows B.A. Long term antithyroid treatment in hyperthyroidism. JAMA 242: 2408, 1979.

    Article  CAS  PubMed  Google Scholar 

  28. Madec A.M., Laurent M.S., Lorcy Y., Leguerrier A., Rostagnat-Stefanutti A., Orgiazzi J., Allannic M. Thyroid stimulating antibodies: an aid to the strategy treatment of Graves’ disease. Clin. Endocrinol. (Oxf.) 21: 247, 1984.

    Article  CAS  Google Scholar 

  29. Greer M.A., Kamper H., Bouma D.J. Short term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. N. Engl. J. Med. 297: 173, 1977.

    Article  CAS  PubMed  Google Scholar 

  30. Bing R.F., Rosenthal F.D. Early remission in thyrotoxicosis produced by short courses of treatment. Acta Endocrinol. (Copenh.) 100: 221, 1982.

    CAS  Google Scholar 

  31. Bouma D.J., Kammer H., Greer M.A. Follow-up comparison of short term 1-year antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. J. Clin. Endocrinol. Metab. 25: 1138, 1982.

    Article  Google Scholar 

  32. Meng W., Meng S., Stöwhas H., Männchen E., Ventz M., Hampel R. Ergebnisse der thyreostatischen Langzeittherapie der Hyperthyreose. Einflub der Struma, der Orbitopathie und der Behandlungsdauer. Deuts. Ges. Wesen. 37: 1956, 1982.

    Google Scholar 

  33. Fenzi G., Hashizume K., Roudebush C.P., DeGroot L.J. Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. J. Clin. Endocrinol. Metab. 48: 572, 1979.

    Article  CAS  PubMed  Google Scholar 

  34. McGregor A.M., Rees Smith B., Petersen M.M., Miller H., Dewar P.J. Prediction of relapse in hyperthyroid Graves’ disease. Lancet 1: 1101, 1980.

    Article  CAS  PubMed  Google Scholar 

  35. Edan G., Massart C., Poirier J.Y., Lé Reun M., Hespel J.P., Ledech G., Simon M. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves’ disease. Br. Med. J. 298: 359, 1989.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Section, General Hospital of Vigo, PO BOX 1691, 36201, Vigo (Galicia), Spain

    Ricardo V. G. García-Mayor, C. Páramo, R. Luna Cano & J. C. Galofré

  2. Unit of Biomedical Research, General Hospital of Vigo, Vigo, Spain

    L. F. Pérez Méndez

  3. Endocrine Laboratory, General Hospital of Vigo, Vigo, Spain

    A. Andrade

Authors
  1. Ricardo V. G. García-Mayor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Páramo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Luna Cano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. F. Pérez Méndez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. C. Galofré
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Andrade
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by Grant FISss 89/127-F-3 from Fondo de Investigación of Spanish Ministry of Health.

Rights and permissions

Reprints and permissions

About this article

Cite this article

García-Mayor, R.V.G., Páramo, C., Cano, R.L. et al. Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 15, 815–820 (1992). https://doi.org/10.1007/BF03348811

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03348811

Key-words

Search

Navigation